Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA says Cerebral Health makes unapproved claims

This article was originally published in The Tan Sheet

Executive Summary

Cerebral Health's marketing claims that Alzenia Anti-Aging Brain Formula, Memeron Memory Enhancer, Neurotine Amino Acid Brain Fuel, Synaptine Nootropic and Cognitive Enhancer, Synaptine Blue Brain Health Supplement and Synaptine Elite Maximum Strength Nootropic prevent or ease symptoms of Alzheimer's disease, Parkinson's disease, strokes, Down's syndrome and other mental ailments render the products unapproved new drugs. In a Jan. 7 warning letter to the Jupiter, Fla., firm, FDA says the products' ingredients are not generally recognized as safe and effective for the mentioned uses

You may also be interested in...



Sales Already Growing As Vascepa Secures Cardio Approval

Company forecasts 2020 sales as high as $700m after regulator grants broad label.

Another EU MDR Notified Body In The Netherlands

Last week, the Commission  revealed that three more notified bodies had been designated; but their listings had not been made official. Now we learn that one of the three is in the Netherlands as the first listing takes place.

Belgium Outlaws OTC Cough And Cold Combination Drugs

Safety concerns prompt Belgium's drug regulator to order all OTC fixed combination products for coughs and colds removed from shelves.

Topics

UsernamePublicRestriction

Register

PS103746

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel